Regulation S-K

Oculus Announces Joining AWS ISV Partner Path

Retrieved on: 
Tuesday, June 1, 2021
SEC filings, Communication, Forward-looking statement, United States Securities Regulation, Private Securities Litigation Reform Act, United States securities law, Federal government of the United States, Financial markets, U.S. Securities and Exchange Commission, United States corporate law, Regulation S-K

This news release contains forward-looking statements and information within the meaning of applicable securities laws (collectively, "forward-looking statements"), including the United States Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This news release contains forward-looking statements and information within the meaning of applicable securities laws (collectively, "forward-looking statements"), including the United States Private Securities Litigation Reform Act of 1995.
  • All statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
  • Such forward-looking statements include, among others, statements as to the intended uses of the proceeds received from the Offering.
  • These reports and Oculus' public filings are available at www.sec.gov in the United States and www.sedar.com in Canada.

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Monday, May 31, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Monday, May 31, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Monday, May 31, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Monday, May 31, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

Retrieved on: 
Monday, May 31, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

DGAP-News: APONTIS PHARMA AG: Notification on the implementation of stabilization measures

Retrieved on: 
Friday, May 28, 2021
Financial markets, Finance, U.S. Securities and Exchange Commission, Stock market, Money, 73rd United States Congress, Securities Act, Security, United States securities law, Investment Advisers Act, Regulation S-K

There will be no public offering of the securities in the United States.

Key Points: 
  • There will be no public offering of the securities in the United States.
  • The Securities of the Company have not been, and will not be, registered under the Securities Act.
  • This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.
  • Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Friday, May 28, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

Retrieved on: 
Friday, May 28, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Friday, May 28, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Regulation S-K, Group decision-making

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO